Inventiva S.A. American Depository Shares (IVA) vs Oric Pharmaceuticals (ORIC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Inventiva S.A. American Depository Shares (IVA) has outperformed Oric Pharmaceuticals (ORIC) over the past year, losing 27.0% versus a loss of 36.7%. Over five years, ORIC leads with a -48.6% price change compared with -76.5% for IVA. Oric Pharmaceuticals is the larger company by market cap ($764.9 million vs $750.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IVA | ORIC |
|---|---|---|
| Share price | $3.14 | $7.36 |
| Market cap | $750.78M | $764.94M |
| 1-day change | -8.99% | -4.42% |
| YTD return | -32.47% | -10.02% |
| 1-year return | -26.98% | -36.66% |
| 5-year return | -76.53% | -48.64% |
| EPS (TTM) | $-0.62 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-49.63M | $-129.47M |
| 52-week high | $7.29 | $14.68 |
| 52-week low | $2.82 | $7.23 |
| Distance from 52-week high | -56.93% | -49.86% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +359.24% | +194.97% |
| Average volume | 2.40M | 1.59M |
| Shares outstanding | 239.10M | 103.93M |
| Employees | 87 | 111 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Inventiva S.A. American Depository Shares
IVA stock →Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
About Oric Pharmaceuticals
ORIC stock →ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees
IVA vs ORIC FAQ
Which is bigger, Inventiva S.A. American Depository Shares or Oric Pharmaceuticals?
Oric Pharmaceuticals (ORIC) is larger, with a market capitalization of $764.94M compared with $750.78M for Inventiva S.A. American Depository Shares (IVA).
Which stock has performed better over the past year, IVA or ORIC?
IVA returned -26.98% over the past 12 months, compared with -36.66% for ORIC (price return, excluding dividends). Past performance does not predict future results.
Are Inventiva S.A. American Depository Shares and Oric Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.